Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Indian PM Narendra Modi at the dedication ceremony of Kiran Multispeciality Hospital in Surat Prime Minister Narendra Modi said his government could adopt a legal framework whereby doctors will have to prescribe cheaper generic medicines than brand-name drugs equivalent to Patients. Modi said his government adopted a health policy after 15 years and limited the prices of drugs and stents, which angered some pharmaceutical companies.

  • AstraZeneca announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy. Tagrisso is the first and only approved medicine in the US indicated for NSCLC patients who have tested positive for the EGFR T790M mutation, and efficacy data suggest it may be a new standard of care for these patients.

  • Cipla Ltd, a global pharmaceutical company, today announced that its wholly owned subsidiary in USA — Cipla USA Inc. has signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Limited (MEDRx) to further develop and commercialize MRX-4TZT, a Tizanidine1 patch for the management of Spasticity.

  • HitGen Ltd. is pleased to announce that the company has entered into a multi-year research collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to build and screen novel DNA-encoded libraries (DELs) in order to potentially discover unique small molecule leads to be used in drug development. Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for Pfizer’s drug discovery efforts. In addition, HitGen will screen their own DELs, consisting of billions of compounds, against a selected number of Pfizer’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to Pfizer for further research and development. Pfizer will fund the research at HitGen.

  • Hallstar, a specialty chemical company based in Chicago, has been awarded the 2017 Global in-cosmetics® Innovation Silver Prize for its revolutionary new anti-aging ingredient, Micah. Winners were announced at the in-cosmetics® conference in London on April 4th. The awards are given to honor the development of a novel active or functional ingredient combining innovative science and product features in a way that demonstrates substantial benefits to manufacturers and end-users.

    [adsense:336x280:8701650588]

Subscribe to Pharma News